Lens opacities in thalassemia.
This is the first case report of cataracts in patients with thalassemia major. Desferrioxamine, an iron-chelating agent is being used with increasing frequency in the treatment of transfusion-induced iron overload. There has been some concern in the literature about possible cataract formation with use of this drug. It is therefore important to document any lens opacities seen prior to administration of desferrioxamine, or record the appearance of lens opacities after its use. The possible eitology of these lens opacities is discussed.
D000293:Adolescent; D000328:Adult; D001168:Arthritis / Q000150:complications; D002386:Cataract / Q000139:chemically induced* / Q000175:diagnosis; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000150:complications; D006333:Heart Failure / Q000150:complications; D006801:Humans; D007223:Infant; D008297:Male; D013789:Thalassemia / Q000150:complications / Q000188:drug therapy*
D003676:Deferoxamine